CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW
CERO THERAPEUTICS HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.01+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $253.05K
- P/E (TTM)
- –
- Dividend yield
- 172833.33%
Ownership
Institutional holdings as of Dec 31, 2025, from 13F filings
Held by institutions
0M
Shares held, 13F filers
Institutional holders
0
0 new, 11 sold out
Net institutional buying
-0M
In Q4 2025
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lawrence Corey | 8,529,316 | 5.70% | 13G (passive) | Dec 10, 2024 |
| Steven Boyd | 584,548 | 9.99% | 13G (passive) | Mar 31, 2025 |
| Brian G. Atwood | 511,800 | 9.90% | 13D (active) amendment | Mar 31, 2025 |
| SMS Revocable Trust | 21,067,956 | – | 13G (passive) amendment | Sep 24, 2024 |
| Jurgen van de Vyver | 1,015,000 | 6.80% | 13D (active) amendment | Feb 14, 2024 |
Top institutional holders
13F holdings as of Sep 30, 2025
| Holder | Shares | % of CERO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Parallel Advisors, LLC | 121,000 | – | $615.89K | −99,000 | 0.01% |
| ARCH Venture Management, LLC | 22,389 | – | $113.96K | – | 0.02% |
| Susquehanna International Group, Llp | 10,244 | – | $52.14K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 1,299 | – | $6.61K | +615 | 0.00% |
| FNY Investment Advisers, LLC | 1,050 | – | $5 | – | 0.00% |
| Citigroup Inc | 968 | – | $4.93K | New | 0.00% |
| SBI Securities Co., Ltd. | 18 | – | $92 | – | 0.00% |
| UBS Group AG | 6 | – | $30 | −2,619 | 0.00% |
| Bank Of America Corp /De/ | 3 | – | $15 | +1 | 0.00% |
| Jones Financial Companies Lllp | 3 | – | $16 | – | 0.00% |
| Royal Bank of Canada | 1 | – | $0 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q4 2025 | 0 | 0M | 0 / 0 | 0 / 11 | 0M | 0M |
| Q3 2025 | 11 | 0M | 3 / 2 | 2 / 0 | 0M | 0M |
| Q2 2025 | 8 | 0M | 8 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Christopher B. Ehrlich | Chairman and CEO, Director | 11,091,654 | Jan 9, 2026 |
| Kristen Pierce | Chief Development Officer | – | Jan 9, 2026 |
| Andrew Albert Kucharchuk | Chief Financial Officer | – | Jan 9, 2026 |
| Eric Francois | Director | – | Apr 21, 2026 |
| Shami Patel | Director | 1,120,254 | Jan 9, 2026 |
| Lindsey Rolfe | Director | – | Jan 9, 2026 |
| Michael Byrnes | Director | – | Jan 9, 2026 |
| Kathleen Laporte | Director | 989,325 | Jan 9, 2026 |
| Brian G. Atwood | Director | 516,784 | Jan 9, 2026 |
| Mitchell William Kossar | 10% owner | 18,962,419 | Dec 13, 2024 |
| YK Bioventures Opportunities GP I, LLC | 10% owner | 13,005,169 | Dec 13, 2024 |
| YK Bioventures Opportunities Fund I, L.P. | 10% owner | – | Dec 13, 2024 |
| Gary Kahing Yeung | 10% owner | 25,870,783 | Dec 13, 2024 |
| Stuart M. Sloan | 10% owner | 21,067,956 | Nov 20, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian G. Atwood Director | Mar 31, 2025 | Option exercise | +294,460 | – | – | 490,534 |
| YK Bioventures Opportunities GP I, LLC 10% owner | Dec 13, 2024 | Sale | −2,998,908 | $0.06 | $179.93K | 13,005,169 |
| YK Bioventures Opportunities GP I, LLC 10% owner | Dec 12, 2024 | Sale | −1,614,541 | $0.07 | $113.02K | 16,004,077 |
| YK Bioventures Opportunities GP I, LLC 10% owner | Dec 11, 2024 | Sale | −1,343,801 | $0.08 | $107.50K | 17,618,618 |
| Mitchell William Kossar 10% owner | Dec 10, 2024 | Sale | −1,570,947 | $0.09 | $141.39K | 18,962,419 |
| Mitchell William Kossar 10% owner | Dec 9, 2024 | Sale | −850,543 | $0.11 | $93.56K | 20,533,366 |
| Mitchell William Kossar 10% owner | Dec 6, 2024 | Sale | −1,236,874 | $0.12 | $148.42K | 21,383,909 |
| Mitchell William Kossar 10% owner | Oct 10, 2024 | Sale | −3,250,000 | $0.10 | $325.00K | 22,620,783 |
| Stuart M. Sloan 10% owner | Sep 25, 2024 | Sale | −532,486 | $0.10 | $53.25K | 21,067,956 |
| Brian G. Atwood Director | Sep 25, 2024 | Option exercise | +19,358,578 | – | – | 19,607,313 |
| Kathleen Laporte Director | Sep 25, 2024 | Option exercise | +965,997 | – | – | 965,997 |
| Christopher B. Ehrlich Interim Chairman and CEO, Director | Sep 25, 2024 | Option exercise | +5,312,983 | – | – | 5,791,808 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +148,208 | – | – | 248,735 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +100,527 | – | – | 100,527 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +148,208 | – | – | 248,735 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +100,527 | – | – | 100,527 |
| Caroline M. Loewy Director | Feb 14, 2024 | Other | +5,828 | – | – | 5,828 |
| Douglas Carl Fisher President | Feb 14, 2024 | Other | +43,300 | – | – | 43,300 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +148,208 | – | – | 248,735 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +100,527 | – | – | 100,527 |
| Brian G. Atwood Chief Executive Officer, Director | Feb 14, 2024 | Other | +125,000 | – | – | 125,000 |
| Kathleen Laporte Director | Feb 14, 2024 | Other | +5,828 | – | – | 5,828 |
| Daniel E. Geffken Chief Financial Officer | Feb 14, 2024 | Other | +10,002 | – | – | 10,002 |
| Christopher B. Ehrlich Director | Feb 14, 2024 | Other | +3,600 | – | – | 3,600 |
| Christopher B. Ehrlich Director | Feb 14, 2024 | Other | +478,825 | – | – | 478,825 |
| Christopher B. Ehrlich Director | Feb 14, 2024 | Other | −4,171,246 | – | – | 1,000,000 |
| Christopher B. Ehrlich Director | Feb 14, 2024 | Other | −1,125,000 | – | – | 4,171,246 |
| Phoenix Biotech Sponsor, Llc 10% owner | Feb 14, 2024 | Other | −4,171,246 | – | – | 1,000,000 |
| Phoenix Biotech Sponsor, Llc 10% owner | Feb 14, 2024 | Other | −1,125,000 | – | – | 4,171,246 |
| Barbara Kosacz Director | Feb 14, 2024 | Other | +5,828 | – | – | 5,828 |
| Douglas Carl Fisher President | Oct 8, 2021 | Other | +10,000 | – | – | 10,000 |
| Christopher B. Ehrlich CEO and Secretary, Director, 10% owner | Oct 8, 2021 | Other | +36,733 | $10.00 | $367.33K | 699,996 |
| Phoenix Biotech Sponsor, Llc 10% owner | Oct 8, 2021 | Other | +36,733 | $10.00 | $367.33K | 699,996 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.